ALXN2350
/ AstraZeneca
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
May 11, 2026
DCMRestore: ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
(clinicaltrials.gov)
- P1/2 | N=6 | Recruiting | Sponsor: Alexion Pharmaceuticals, Inc.
Trial initiation date • Cardiomyopathy • Cardiovascular • Gene Therapies • BAG3
February 18, 2026
ALXN2350-DCM-201: A Phase 1/2 study of ALXN2350 in adult participants with BAG3-associated dilated cardiomyopathy
(clinicaltrialsregister.eu)
- P1/2 | N=8 | Recruiting | Sponsor: Alexion Pharmaceuticals Inc.
New P1/2 trial • Cardiomyopathy • Cardiovascular • Gene Therapies • BAG3
January 14, 2026
DCMRestore: ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
(clinicaltrials.gov)
- P1/2 | N=6 | Recruiting | Sponsor: Alexion Pharmaceuticals, Inc. | N=18 ➔ 6
Enrollment change • Cardiomyopathy • Cardiovascular • Gene Therapies • BAG3
December 03, 2025
DCMRestore: ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
(clinicaltrials.gov)
- P1/2 | N=18 | Recruiting | Sponsor: Alexion Pharmaceuticals, Inc. | Trial primary completion date: Jul 2030 ➔ Jan 2032 | Not yet recruiting ➔ Recruiting
Enrollment open • Trial primary completion date • Cardiomyopathy • Cardiovascular • Gene Therapies
October 21, 2025
DCMRestore: ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
(clinicaltrials.gov)
- P1/2 | N=18 | Not yet recruiting | Sponsor: Alexion Pharmaceuticals, Inc.
New P1/2 trial • Cardiomyopathy • Cardiovascular • Gene Therapies
1 to 5
Of
5
Go to page
1